Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain

Abstract

The purpose of the current study was to investigate the plausibility of delivery of ziconotide to the cerebrospinal fluid (CSF) via intranasal administration. Ziconotide was administered either in the form of solution or Kolliphor P 407 gels (KP 407) intranasally in Sprague-Dawley rats. The effect of incorporation of chitosan in the formulation was also investigated. Time course of drug in the CSF was investigated by collecting CSF from cisterna magna. Pharmacokinetics of ziconotide in CSF following intrathecal and intravenous (i.v) administration of ziconotide was investigated. Upon intrathecal administration the elimination rate constant of ziconotide in CSF was found to be 1.01 ± 0.34 h−1. The Cmax and Tmax of ziconotide in CSF following intravenous administration were found to be 37.78 ± 6.8 ng/mL and ~2 h respectively. The time required to attain maximum concentration (Tmax) in CSF was less upon intranasal administration (15 min) compared to i.v administration (120 min). Presence of chitosan enhanced the overall bioavailability of ziconotide from intranasal solution and gel formulations. The elimination rate constant of ziconotide in CSF following intranasal and intravenous administration of ziconotide solution was found to be 0.54 ± 0.08 h−1 and 0.42 ± 0.10 h−1 respectively. Whereas, intranasal administration of ziconotide in the form of in situ forming gel lowered the elimination rate significantly. These results suggest that intranasal administration could be a potential noninvasive and patient compliant method of delivering ziconotide to CSF to treat chronic pain.

A Screening of Permeation Enhancers for Transdermal Delivery of Propofol

“…Chemical penetration enhancers are widely used to improve the topical and transdermal delivery of drugs due to their patient compliance and lower cost [7,12]. In this project, ten penetration enhancers were investigated to improve the permeation of propofol across the porcine full thickness skin.…”

Application of Hot Melt Extrusion in Pharmaceutical 3D Printing

“…3D printing is used to produce products like highly porous products (orally disintegrating), toroidal products (approximately zero-order release), Complex drug-device combination products, personalized dosing (for potent drugs and children), drug-loaded implants (matching the anatomy of individual patients), polypills (combination of different drugs) and ocular implant. 3D printing facilitates personalization by changing the digital designs which is more feasible than changing equipment design with less operational cost [10][11][12]. 3D printing is synonymously used with additive manufacturing and rapid prototyping technology.…”

Recent Updates in the Formulation Strategies to Enhance the Bioavailability of Drugs Administered via Intranasal Route

“…Manda et al investigated the ability of delivering ziconotide via intranasal route. Ziconotide when delivered using poloxomer as a vehicle could not only attain therapeutic concentration rapidly but also prolong the release of ziconotide, maintain therapeutic levels in CSF for a longer period of time compared to solution and reduce the frequency of administration [53].…”